Biotech–pharma alliances: Strategies, structures and financing

10.5912/jcb91 ◽  
2004 ◽  
Vol 10 (4) ◽  
Author(s):  
Tyzoon Tyebjee ◽  
Jill Hardin
Keyword(s):  
Drug Discovery ◽  
Case Studies ◽  
Financial Instruments ◽  
Drug Discovery And Development ◽  
Development Cycle ◽  
Biotechnology Companies ◽  
Strategic Logic

The drug discovery and development industry is under intense pressure to become more efficient and develop drugs better, faster, cheaper. Consequently, pharmaceutical and biotechnology companies are entering into alliances in an effort to utilise each other's talents, exploit each other's specialisations, and create more value. In this paper, the economics of the drug discovery and development cycle are examined to identify the economic and strategic logic of the alliances. The financial instruments commonly used to structure the alliances are discussed with example case studies.

A Role for Virtual Biotechnology Companies in Drug Discovery and Development?

2013 ◽  
Vol 19 (3) ◽  
Author(s):  
Dianne Nicol ◽  
Johnathon Liddicoat ◽  
Christine Critchley
Keyword(s):  
Drug Discovery ◽  
Business Model ◽  
Early Stage ◽  
Policy Implications ◽  
Pharmaceutical Companies ◽  
Virtual Model ◽  
Journal Articles ◽  
Drug Discovery And Development ◽  
Biotechnology Companies ◽  
Novel Method

The orthodox business model of many drug discovery and development companies centres on adding value to early-stage discoveries prior to engaging with large pharmaceutical companies to bring products to market. Anecdotal observations suggest some companies are moving to a ‘virtual’ business model - instead of employing in-house scientists, a skeletal management team runs the company and out-sources all research and development. This article presents a novel method to determine whether companies are virtual, based on author bylines in peer-reviewed journal articles. Applying this method to Australian companies in this sector, the size of the cohort identified as virtual was much larger than anticipated, around 52%. The accuracy of this method has been verified statistically using interview data. This article discusses the value and limitations of this method, positing that it can be used to analyse industry and policy implications that may result from widespread adoption of the virtual model

scholarly journals A Triple Helix systems perspective of UK drug discovery and development: A systematic review of REF impact case studies

2020 ◽  
pp. 095042222096934
Author(s):  
Leonard Kelleher ◽  
Anna Zecharia
Keyword(s):  
Drug Discovery ◽  
Case Studies ◽  
Strategic Alliances ◽  
Triple Helix ◽  
Systems Approach ◽  
Research Policy ◽  
Empirical Studies ◽  
Innovation System ◽  
Theory Development ◽  
Drug Discovery And Development

UK drug discovery and development is increasingly being shaped through a complex interaction of research, policy and practice. However, our understanding of this innovation system is partially due to the dearth of systems-level empirical studies and to simplistic conceptual approaches. This study uses a Triple Helix systems approach to illustrate how a novel database of Research Excellence Framework 2014 impact case studies may be used both to advance empirical understanding of UK drug discovery and development and for theory development. The authors refine the Triple Helix system by identifying relationships between its three components (academia, government and industry) and various social actors. The paper also make two contributions to practice, concerning the relative unimportance for impact generation of geographical clusters relative to strategic alliances, network linkages and knowledge spillovers, and the strong bias towards national and Anglo-American academic–practitioner linkages with few or no links to emerging knowledge economies.

Sitagliptin: a potential drug for the treatment of SARS-CoV-2?

2020 ◽  
Author(s):  
Sanaa Bardaweel
Keyword(s):  
Clinical Trials ◽  
Drug Discovery ◽  
Antimalarial Drug ◽  
Drug Repurposing ◽  
Spike Protein ◽  
Diabetic Patients ◽  
Potential Drug ◽  
Chemokine Production ◽  
Drug Discovery And Development ◽  
Sequence Identity

Recently, an outbreak of fatal coronavirus, SARS-CoV-2, has emerged from China and is rapidly spreading worldwide. As the coronavirus pandemic rages, drug discovery and development become even more challenging. Drug repurposing of the antimalarial drug chloroquine and its hydroxylated form had demonstrated apparent effectiveness in the treatment of COVID-19 associated pneumonia in clinical trials. SARS-CoV-2 spike protein shares 31.9% sequence identity with the spike protein presents in the Middle East Respiratory Syndrome Corona Virus (MERS-CoV), which infects cells through the interaction of its spike protein with the DPP4 receptor found on macrophages. Sitagliptin, a DPP4 inhibitor, that is known for its antidiabetic, immunoregulatory, anti-inflammatory, and beneficial cardiometabolic effects has been shown to reverse macrophage responses in MERS-CoV infection and reduce CXCL10 chemokine production in AIDS patients. We suggest that Sitagliptin may be beneficial alternative for the treatment of COVID-19 disease especially in diabetic patients and patients with preexisting cardiovascular conditions who are already at higher risk of COVID-19 infection.

Sign in / Sign up

Export Citation Format

Share Document